Biotechnology company developing and deploying psychedelic inspired medicines to treat addiction and mental conditions MindMed Inc. (NASDAQ: MNMD) (NEO: MMED) announced Stephen Hurst has resigned from his position as a director to the company’s board of directors.
This development was announced during the past weekend by the company’s chief executive officer, Robert Barrow, who thanked Hurst for his unlimited guidance and contribution during his tenure at the company’s board of directors.
“On behalf of MindMed, the Board of Directors, and the Executive team, I thank Steve for his significant contributions and strategic guidance in bringing the Company to this stage of development. The co-founders and early leadership of MindMed have been instrumental in establishing the company and its strong foundation. Their work, vision, and the programs that they initiated will continue to serve as the basis for our execution of the company’s mission. As we approach important milestones across our clinical development programs, we are extremely grateful for Steve’s effort to enable this progress,” said the CEO.
On the other side, Hurst thanked the whole team of MindMed where he has worked for over a decade he however, didn’t disclose what his next move will be but he expressed great confidence in current team at the helm of the company.
“MindMed is the culmination of my career and more than a decade of work to bring the benefits of psychedelic-inspired medicines to patients struggling with addiction and mental illness. With the recent appointment of two seasoned Directors and a brilliant Chief Executive Officer, I have the greatest confidence in the team’s ability to guide the Company through this next phase of continued progress toward the realization of our highest aspirations,” said Hurst.
